Contrast Media

Contrast media, also called contrast agents, are used to enhance the blood and perfusion in tissues. This includes iodine based contrast for on computed tomography (CT), gadolinium based agents for MRI and lipid bubble contrast agents used in ultrasound.

As the world, particularly the imaging community, is aware, disruptions in a pharmaceutical supply chain have impacted the global availability, and shortage of, iohexol iodinated contrast media (ICM), a common agent used in a multitude of CT and X-ray exams.
Feature | Contrast Media | By Christine Book
Contrast Media Supply Shortage: How and What Now?

The theme “Everyday progress” seems appropriate for the imaging community in 2022. What a year it’s been. Supply ...

Time September 14, 2022
arrow
EHR screenshot showing sidebar text displayed to referring clinicians after placing orders for body CT (neck, chest, or abdomen and pelvis), describing iohexol shortage and providing appropriate strategies for iodinated contrast media conservation.
News | Contrast Media
EHR Interventions for Contrast Media Shortage Impact CT Utilization

August 3, 2022 — According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), electronic health ...

Time August 03, 2022
arrow
Bracco Diagnostics has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron® (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage.
News | Contrast Media
FDA Grants Import Discretion of Bracco’s Iodinated Contrast Medium Iomeron (iomeprol injection) to Address Supply Shortages

August 2, 2022 – A new update has been announced as the radiology world continues to address supply disruptions of ...

Time August 02, 2022
arrow
Iodixanol Injection, USP is the first U.S. FDA-approved generic iso-osmolar, dimeric iodinated contrast media agent, which is used during diagnostic x-ray-based imaging such as computed tomography (CT) scans
News | Contrast Media
Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

July 18, 2022 — Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the ...

Time July 18, 2022
arrow
Philips Angio CT
Sponsored Content | Case Study | SPECT-CT
Making the Invisible Visible: Spectral CT 7500 Transforms Patient Care with First-time-right Diagnosis

A patient’s chance of recovery can be directly impacted when a diagnosis is missed or delayed. To get the right ...

Time July 06, 2022
arrow
Contrast media is used to improve diagnostic imaging, and the shortage has affected millions of examinations.
News | Contrast Media
Global Contrast Media Shortage: Strategies for Conservation

July 5, 2022 — In April 2022, a shutdown of Shanghai due to China’s “zero COVID” policy caused a global shortage of ...

Time July 05, 2022
arrow
Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of June
Feature | Radiology Business | By Melinda Taschetta-Millane
ITN's Top 10 Most-read Content for June

Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of ...

Time July 05, 2022
arrow
CM = contrast media; CO2 = carbon dioxide; Gd = gadolinium; IVUS = intravascular ultrasound. Image courtesy of the Journal of Vascular and Interventional Radiology
News | Contrast Media
Global Contrast Media Shortage Means Urgent Changes in Interventional Radiology Practices

June 23, 2022 — Supply chain disruptions have created critical shortages of Omnipaque (iohexol) and Visipaque (iodixanol ...

Time June 23, 2022
arrow
Today, GE Healthcare issued a statement that it expects production capacity from its Shanghai facility to be close to 100% starting Monday, June 6, following the easing of local COVID-19 restrictions.
News | Contrast Media
GE Healthcare Issues Update on Iodinated Contrast Media

June 2, 2022 — Today, GE Healthcare issued a statement that it expects production capacity from its Shanghai facility to ...

Time June 02, 2022
arrow
Top 10 ITN content for the Month of May 2022
Feature | Radiology Business | By Melinda Taschetta-Millane
ITN's Top 10 Most-read Content for May

Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of ...

Time June 01, 2022
arrow
The current shortage of iodinated contrast in the United States due to the COVID-19 related production shutdown in China is causing severe disruptions in patient care. A new Harvey L. Neiman Health Policy Institute study outlines the most frequently used computed tomography (CT) services performed on Medicare beneficiaries as focus areas for mitigation strategies for the greatest overall impact.
News | Contrast Media
New Study Informs Mitigation Strategies for Contrast Shortage in CT by Identifying Promising Areas of Focus

June 1, 2022 — The current shortage of iodinated contrast in the United States due to the COVID-19 related production ...

Time June 01, 2022
arrow
Patented artificial intelligence technology eliminates the need for gadolinium-based contrast agents in MRI exams
News | Artificial Intelligence
Imaging Biometrics Submits FDA 510(k) Application for IB Zero G

May 31, 2022 — Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, announced it has submitted an FDA 510(k) ...

Time May 31, 2022
arrow
Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare Omnipaque iohexol iodinated contrast media (ICM) for radiologic examinations.
News | Contrast Media
New Report Provides Strategies for Managing Contrast Shortage

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
Decision tree for manual review of currently scheduled contrast-enhanced CT examinations in the event that iodinated contrast supply is critically low. CECT = contrast-enhanced CT. GBCA = gadolinium-based contrast agent. NCCT = non-contrast CT. US = ultrasound.
News | Contrast Media
AJR Publishes Best Practices for Iodinated Contrast Media Shortage

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware of the current global shortage of iodinated contrast media.
News | Contrast Media
Statement from the ACR Committee on Drugs and Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
The global contrast media market is projected to reach $5.9 billion by 2026 from $4.9 billion in 2021, at a CAGR of 3.7% during the forecast period.
Feature | Contrast Media
Contrast Media/Contrast Agent Market

The global contrast media market is projected to reach $5.9 billion by 2026 from $4.9 billion in 2021, at a CAGR of 3.7% ...

Time May 03, 2022
arrow
Lawrence N. Tanenbaum, MD FACR is Vice President/Chief Technology Officer Director of CT, MR, and Advanced Imaging for RadNet with 37+ years experience in the medical field. He is a member of editorial boards of several journals/educational organizations and reviewer for scientific journals. He has authored 100+ scholarly and peer-reviewed articles, chairs educational/academic meetings, and has delivered 2000+ invited global lectures.
Sponsored Content | Case Study | Contrast Media Injectors
Case Studies with Lawrence N. Tanenbaum, MD FACR Using Macrocyclic CLARISCAN (gadoterate meglumine) Injection for Intravenous Use

Product Indications and Use: CLARISCAN (gadoterate meglumine) is a gadolinium-based contrast agent indicated for ...

Time May 03, 2022
arrow
NEXO[DOSE] dashboard
Sponsored Content | Blog | Radiation Dose Management
Effective Radiation Dose Management Improves Imaging Practices, Patient Safety and Ensures Compliance

Early-stage detection is key to the prevention of life-threatening diseases; however, limited access to data hinders the ...

Time April 11, 2022
arrow
Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Centralized Application for Marketing Authorization to the European Medicine Agency (EMA) for Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA).
News | Contrast Media
Gadopiclenol Marketing Authorization Dossier Submissions Accepted for Review by EMA and FDA

April 6, 2022 — Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products ...

Time April 06, 2022
arrow
EmpowerMR Injector System
Sponsored Content | Blog | Contrast Media Injectors
BLOG: Advanced Injector System Provides Greater Control and Accelerates Patient Care

Medical imaging and contrast use have become an integral part of the diagnostic process to determine the best ...

Time February 28, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now